N/A N=169 Improving ADHD Behavioral Care
ADHD
Primary: Rates of Behavioral Treatment — 44; 64 Participants — p=.535
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=31 Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 1; 0; 2 Participants
Phase 2 N=7 MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
Diffuse Intrinsic Pontine Glioma
Primary: Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events — 0.142; 0.142; 0.142; 0.142 proportion of participants
Phase 3 N=195 An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread
Colorectal Cancer
Primary: Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR) — 11.86; 11.93 Months — p=0.3022
N/A N=52 Development and Testing of a Behavioral Activation Mobile Therapy for Elevated Depressive Systems
Depression
Primary: Average Decrease of Beck Depression Inventory-II Score — -12.21; -13.36; -7.75 Decrease in units on scale — p=<.05
Phase 1 N=40 A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults
Respiratory Syncytial Virus Infections
Primary: Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose of Vaccination — 1; 0; 17; 1 Participants
Phase 2 N=7,192 Cooking for Health Optimization With Patients
Cardiovascular Diseases · Cardiovascular Risk Factor · Nutrition Disorders
Primary: High or Medium (Versus Low) Mediterranean Diet Adherence — 55.99; 50.53 percentage of arm
N/A N=316 Effects of Family Sodium Watcher Program on Outcomes in Heart Failure Patient-Family Caregiver Dyads
Heart Failure
Primary: Patients' Adherence to Sodium-restricted Diet Assessed by Urinary Sodium Excretion Levels — 4390.2; 4048.9; 3338.1; 4402.9 mg/day
Phase 2 N=25 Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
Cirrhosis · Hepatocellular Carcinoma
Primary: Response (at Least a 50% Reduction in Liver Phospho-EGFR Staining) — 3; 3; 6 Participants
Phase 2 N=6 A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients
Sanfilippo Syndrome Type A (MPS IIIA)
Primary: Safety as Measured by Adverse Events Frequencies (by Type and Severity) — 174; 355; 0; 1 events
N/A N=201 Short-course Methenamine Hippurate for Prevention of Post-operative UTI
Urinary Tract Infections · Catheter-Related Infections
Primary: Treatment of Clinically Suspected UTI - Using Intent to Treat Analysis — 13; 12 Participants
Phase 2 N=8 Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Breast Cancer
Primary: Number of Participants Who Had a Pathological Complete Response (pCR) — 0; 3 Participants
Phase 2 N=397 Calcium for Out-of-Hospital Cardiac Arrest
Heart Arrest, Out-Of-Hospital
Primary: Number of Participants With Sustained Return of Spontaneous Circulation — 37; 53 Participants
Phase 2 N=84 Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Resectable · Early-stage · NSCLC
Primary: Major Pathological Response Rate — 11.1; 19.0; 30.0; 31.3 Percentage of participants
N/A N=147 Clinical Evaluation of a Silicone Hydrogel Daily Wear Monthly Replacement Contact Lens
Refractive Errors
Primary: Least Squares Mean Contact Lens Corrected Distance Visual Acuity (CLCDVA) at Week 1 Follow-Up — -0.06; -0.06 logMAR